Abstract:Background: Both estrogen receptor a (ER-a) and progesterone receptor (PR) are good prognostic factors and indicators of benefit from endocrine therapy in breast cancer patients. The relationship of the ER-alpha and PR status and the difference in clinical benefit from endocrine therapy in breast cancer is currently unclear. It has been suggested that keratinocyte growth factors (KGFs) are important regulatoty factors in breast cancer. Our laboratory has demonstrated that KGF call act as an estromedin for the stimulation of breast cancer cell growth. Also, KGF stimulates aromatase activity in primary cultured human breast cells. This enzyme is a key to the conversion of androgens to estrogens. In the present study, ER-alpha, two estrogen regulated genes, PR and PTP gamma, KGF and their relationship with endocrine resistance in human breast cancer cells were investigated.Materials and Methods: MCF-7 cells were treated with KGF (1, 5, 10, 20 ng/ml), KGF-13 (0.1, 1, 10 mu M) or vehicles as control for 24 hours. KGF-13 is a potential receptor-binding pentapeptide constructed using the KGF peptide residues 101-105 (RTVAV) as a template, located within the beta 4 - beta 5 loop. Total RNA were isolated and real-time PCR was employed to identify ER-a, PR and PTP gamma gene expressions in response to KGF and KGF-13. Western blot analysis was used to verify the levels of ER-a and PR protein, whereas inummohistochemical staining was used to detect PTP gamma expression in MCF-7 cells. To determine the response of MCF-7 cells to endocrine therapy, MCF-7 was treated with either 20 ng/ml KGF or 10 mu M KGF-13 combined with 1, 3 and 5 mu M of 4-hydroxytamoxifen (4011-Tam). A non-radioactive cell proliferation assay was applied to determine the growth rate of MCF-7 cells. The results of real-time PCR and the cell proliferation assay were analyzed by Student's t-test and p-values of less than 0.05 were considered statistically significant.Results: Our data showed that KGF significantly suppressed ER-a, PR and PTP gamma expression in MCF-7 cells. KGF suppressed ER-a, PR and PTP gamma mRNA to a maximal inhibition at 20 ng/ml by 88%, 57% and 61%, respectively. Western blot analysis and immuno-histochemical staining confirmed the down-regulation of ER-a, PR and PTP gamma by KGF in protein levels. Ten mu M KGF-13 also decreased ER-alpha expression. Teti mu M KGF-13 significantly decreased ER-alpha, PR and PTP gamma mRNA expressions by 51%, 57% and 67%, respectively. These KGF-13-mediated mRNA down-regulations were also observed in protein levels. In a cell proliferation assay, 40H-Tam (3, 5 mu M) induced MCF-7 cell death. KGF and KGF-13 alone did not stimulate MCF-7 cell growth. KGF significantly disrupted 40H-Tam cell killing effects by 1.2- and 1.3-fold at 40H-Tam concentrations of 3 mu M and 5 mu M. respectively. KGF-13 significantly disrupted 40H-Tam cell killing effects by 1.2- and 1.7-fold at 40H-Tam concentrations of 3 mu M and 5 mu M, respectively.Conclusion: Our results suggested that not only ER-alpha and PR but also PTP gamma could be potential bio-makers for growth factor-induced endocrine resistant in breast cancer. KGF might increase the endocrine resistance via decreasing ER-alpha, PR and PTP gamma as well Moreover, the functional analysis of KGF-13 implied possible applications of using short receptor-binding peptides derived from intact KGF as breast cancer therapeutic agents. Thus, our experimental data provided evidence of KGF-induced anti-hormone resistance in human breast cancer and suggested novel strategies for breast cancer via interference with KGF signaling.

Issues Within Keratinocyte Growth Factor (KGF) Research

[Research Progress on Keratinocyte Growth Factor].

Primer on fibroblast growth factor 7 (FGF 7)

Keratinocyte Growth Factor/Fibroblast Growth Factor-7-regulated Cell Migration and Invasion Through Activation of NF-κB Transcription Factors*

Keratinocyte Growth Factor Receptor: a Therapeutic Target in Solid Cancer

[Study on the Function of Keratinocyte Growth Factor on Apoptosis of Oral Mucosal Epithelial Cells].

Physiological functions and underlying mechanisms of fibroblast growth factor (FGF) family members: recent findings and implications for their pharmacological application.

Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: Differentiation response distinguishes KGF from EGF family

Fibroblast growth factors as tissue repair and regeneration therapeutics

Effect of Keratinocyte Growth Factor on Epidermis Cell Proliferation Promoted by Fibroblasts

Phage-Displayed Peptide of Keratinocyte Growth Factor and Its Biological Effects on Epidermal Cells

The role of fibroblast growth factor 7 in cartilage development and diseases

Therapeutic uses of FGFs

Keratinocyte Growth Factor (KGF) Induces Tamoxifen (tam) Resistance in Human Breast Cancer MCF-7 Cells.

Progress in Human Epidermal Growth Factor Research

Keratinocyte Growth Factor (KGF) Regulates Estrogen Receptor-α (Er-Α) Expression and Cell Apoptosis Via Phosphatidylinositol 3-Kinase (pi3k)/akt Pathway in Human Breast Cancer Cells

Keratinocyte Growth Factor Phage Model Peptides Can Promote Epidermal Cell Proliferation Without Tumorigenic Effect.

Fibroblast growth factors, old kids on the new block

Functional Evaluation of Recombinant Human Kerotinocyte Growth Factor in Vivo and in Vitro

Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.

Recombinant Human Keratinocyte Growth Factor Ameliorates Cancer Treatment‐Induced oral Mucositis on a Chip